Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple therapy aims to boost survival in Hard-to-Treat stomach cancers

NCT ID NCT06901531

Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 4 times

Summary

This phase 3 trial tests whether adding the targeted drug zolbetuximab to standard immunotherapy (pembrolizumab) and chemotherapy can help people with advanced stomach or gastroesophageal junction (GEJ) cancer live longer. The study enrolls 500 adults whose tumors have specific markers (CLDN18.2 and PD-L1) but lack HER2. Participants receive either the combination or a placebo with the same chemo and immunotherapy, and are followed to see how long they survive and how the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zolbetuximab (a targeted antibody) combined with pembrolizumab (immunotherapy) and chemotherapy (capecitabine, oxaliplatin, or 5-fluorouracil)
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with advanced stomach or GEJ cancer, potentially extending survival.
What could go wrong
This is an early-phase 3 trial, so results are not yet known. The added drugs may increase side effects, and not all participants may benefit. The cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant has histologically confirmed gastric or Gastroesophageal Junction (GEJ) adenocarcinoma. * Participant has radiographically confirmed, locally advanced, unresectable or metastatic disease within 28 days prior to randomization. * Participant has radiologically evaluable disease (measurable and/or nonmeasurable) according to Response Evaluation Criteria in Solid Tumors (RECIST) V1.1, ≤ 28 days prior to randomization. For participants with only 1 evaluable lesion and prior radiotherapy ≤ 3 months before randomization, the lesion must either be outside the field of prior radiotherapy or have documented progression following radiation therapy. * Participant has Eastern Cooperative Oncology Group Performance Status (ECOG) performance status 0 to 1. * Participant has predicted life expectancy ≥ 12 weeks. * Participant must be a candidate to receive mFOLFOX6 or CAPOX and pembrolizumab. * Female participant is not pregnant and at least 1 of the following conditions apply: * Not a woman of child bearing potential (WOCBP) * WOCBP who has a negative urine or serum pregnancy test at screening (Specific to Japan: with a medical interview), and agrees to follow the contraceptive guidance from the time of informed consent through at least 9 months after the final oxaliplatin administration and 6 months after the final administration of all other study interventions. * Female participant must not be breastfeeding or lactating starting at screening and throughout the investigational period and for 5 half-lives (at least 9 months after the final oxaliplatin administration and 6 months after the final administration of all other study interventions). * Female participant must not donate ova starting at first administration of study intervention and throughout the investigational period, and for 9 months after the final administration of oxaliplatin and for 6 months after final administration of all other study interventions. * Male participant must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period, and for 6 months after final investigational study intervention administration. * Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period and for 6 months after the final investigational study intervention administration. * Male participant must not donate sperm during the treatment period and for 6 months after the final investigational study intervention administration * Participant has a Human Epidermal Growth Factor Receptor 2 (HER2) -negative tumor. * Participant's tumor expresses Claudin18.2 (CLDN18.2) in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central immunohistochemistry (IHC) testing. * Participant's tumor expresses Programmed death ligand (PD-L1) combined positive score (CPS) ≥ 1 as determined by central IHC testing. * Participants with known microsatellite instability-high or mismatch repair deficient status may enroll as long as they meet the PD-L1 positivity criteria. * Participant must meet all of the criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to randomization. In case of multiple central laboratory data within this period, the most recent data should be used. * Participant agrees not to participate in another interventional study while receiving study intervention in the present study. Exclusion Criteria: * Participant has prior severe allergic reaction or intolerance to zolbetuximab or other monoclonal antibodies, pembrolizumab, mFOLFOX6 or CAPOX. * Participant has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent recurrent vomiting. * Participant has significant gastric bleeding and/or untreated gastric ulcers that would preclude the participant from participation. * Participant has unresolved pneumonitis or history of non-infectious pneumonitis such as immune-related pneumonitis, radiation induced pneumonitis. * Participant has history of central nervous system metastases and/or carcinomatous meningitis from gastric/GEJ cancer. * Participant has a known history of a positive test for Human Immunodeficiency Virus (HIV) infection or known active Hepatitis B Surface Antigen (positive HBsAg) or hepatitis C infection. NOTE: Screening for these infections should be conducted per local requirements. * For participants who are negative for HBsAg, but hepatitis B core antibody (HBcAb) positive, a hepatitis B DNA test will be performed and if positive the participant will be excluded. * Participants with positive Hepatitis C virus (HCV) serology, but negative HCV RNA test results are eligible. * Participants treated for HCV with undetectable viral load results are eligible. * Participant has active infection requiring systemic therapy that has not completely resolved within 7 days prior to randomization. * Participant has active autoimmune disease that has required systemic treatment within the past 3 months prior to randomization. Participants with stable autoimmune disease who are receiving physiologic replacement doses of hydrocortisone or its equivalent are allowed. * Participant has a clinically significant disease or comorbidity that may adversely affect the safe delivery of treatment within this study or make the participant unsuitable for study participation. * Participant has another malignancy for which treatment is required. * Participant has known complete Dihydropyrimidine Dehydrogenase (DPD) deficiency (screening for DPD deficiency should be conducted per local requirements). * Participant has known peripheral neuropathy \> grade 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the participant ineligible). * Participant has sinusoidal obstruction syndrome, formerly known as veno-occlusive disease, if present, should be stable or improving. * Participant has significant cardiovascular disease, including any of the following: * Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to randomization. * History of clinically significant ventricular arrhythmias (i.e., sustained; ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes). * QTc interval \> 450 msec for male participants; QTc interval \> 470 msec for female participants. * History or family history of congenital long QT syndrome. * Cardiac arrhythmias requiring anti-arrhythmic medications (participants with rate controlled atrial fibrillation for \> 1 month prior to randomization are eligible). * Participant has ongoing or previous interstitial lung disease, active diverticulitis or peptic ulcerative disease, or solid organ or stem cell transplant or other uncontrolled or clinically significant medical disorders. * Participant has type 1 diabetes mellitus, endocrinopathies stably maintained on appropriate replacement therapy or skin disorders (e.g., vitiligo, psoriasis or alopecia) not requiring systemic treatment are allowed. * Participant has received prior systemic chemotherapy and/or immunotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma, except for a maximum of 1 treatment course of mFOLFOX6 (day 1 to 14) or CAPOX (day 1 to 21) with or without pembrolizumab. However, participants may have received either neo-adjuvant or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies as long as their disease progression occurred at least 6 months after the last dose. Participant who has received treatment with herbal medications that have known antitumor activity \> 28 days prior to randomization is allowed. * Participant has received systemic immunosuppressive therapy, including systemic corticosteroids 14 days prior to randomization. Participant using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single-dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use is allowed. * Participant has had major surgical procedure ≤ 28 days before randomization and has not completely recovered from the surgical procedure ≤ 14 days before randomization. * Participant has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma ≤ 14 days prior to randomization and has NOT recovered from any related toxicity. Palliative radiotherapy is allowed and must be completed \> 14 days prior to randomization. * Participant has received prior CLDN18.2 agents. * Participant received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. * Participant has received other investigational agents or devices concurrently or within 28 days prior to randomization or within 5 half-lives of the drug, whichever is longer. * Participant has any condition which makes the participant unsuitable for study participation. * Participant has any concurrent disease, infection, or co-morbid condition that interferes with the ability of the participant to participate in the study, which places the participant at undue risk or complicates the interpretation of data. * Treatment with brivudine, sorivudine or their chemically related analogues within 28 days prior to randomization or within 5 half-lives of the drug, whichever is shorter, is strictly prohibited. * Pernicious anemia or other anemias due to vitamin B12 deficiency. * Participant has a known history of a positive test for tuberculosis or known active tuberculosis infection. NOTE: Screening for these infections should be conducted per local requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced unresectable gastric adenocarcinoma or cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced unresectable gastric adenocarcinoma or cancer Locally advanced unresectable gastroesophageal junction (GEJ) adenocarcinoma or cancer Metastatic gastric adenocarcinoma or cancer Metastatic gastroesophageal junction (GEJ) adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    193 sites in 18 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Hebei University

    ACTIVE_NOT_RECRUITING

    Baoding, 71000, China

  • Allegheny General Hospital (AGH)-Allegheny Singer Research Institute

    RECRUITING

    Pittsburgh, Pennsylvania, 15212, United States

  • Anhui Provincial Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Hefei, Anhui, 230031, China

  • Barbara Ann Karmanos Cancer Center

    RECRUITING

    Detroit, Michigan, 48201, United States

  • CBCC Global Research - Comprehensive Blood & Cancer Center

    RECRUITING

    Bakersfield, California, 93309, United States

  • Capital Health - Hematology Oncology Specialists

    RECRUITING

    Pennington, New Jersey, 08534, United States

  • Chiba Cancer Center

    ACTIVE_NOT_RECRUITING

    Chiba, Chiba, Japan

  • Dana Farber/Harvard Cancer Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Duke University Medical Center - Duke Cancer Centre

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Franciscan Health Oncology and Hematology Specialists

    RECRUITING

    Indianapolis, Indiana, 46237, United States

  • Fujian Provincial Hospital - Department of Medical Oncology

    ACTIVE_NOT_RECRUITING

    Fuzhou, Fujian, China

  • Gunma University Hospital

    ACTIVE_NOT_RECRUITING

    Maebashi, Gunma, Japan

  • Harbin Medical University Cancer Hospital - Oncology

    ACTIVE_NOT_RECRUITING

    Harbin, Heilongjiang, China

  • Hartford HealthCare - Hartford Hospital

    RECRUITING

    Hartford, Connecticut, 06102, United States

  • Henan Cancer Hospital - Oncology

    ACTIVE_NOT_RECRUITING

    Zhenngzhou, Henan, China

  • Henry Ford Cancer Institute-Henry Ford Hospital

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Hokkaido University Hospital

    ACTIVE_NOT_RECRUITING

    Sapporo, Hokkaido, Japan

  • Holden Comprehensive Cancer Center

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • Houston Methodist Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Hubei Cancer Hospital - Oncology

    ACTIVE_NOT_RECRUITING

    Wuhan, Hubei, 430079, China

  • Hyogo Cancer Center

    ACTIVE_NOT_RECRUITING

    Akashi-shi, Hyōgo, Japan

  • Inova Schar Cancer Institute Clinical Trials

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Kagawa University Hospital

    ACTIVE_NOT_RECRUITING

    Kida-gun, Kagawa-ken, Japan

  • Kanagawa Cancer Ctr Hospital

    ACTIVE_NOT_RECRUITING

    Yokohama, Kanagawa, Japan

  • Kobe City Medical Center General Hospital

    ACTIVE_NOT_RECRUITING

    Kobe, Hyōgo, Japan

  • Kyushu University Hospital (Hematology, Oncology & Cardiovascular medicine)

    ACTIVE_NOT_RECRUITING

    Fukuoka, Fukuoka, Japan

  • Kyushu University Hospital(Gastrointestinal Surgery)

    ACTIVE_NOT_RECRUITING

    Fukuoka, Fukuoka, Japan

  • MedStar Georgetown University Hospital / Lombardi Comprehensive Cancer Center

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

  • Metro Minnesota Community Oncology Research Consortium (MMCORC)

    RECRUITING

    Saint Louis Park, Minnesota, 55426, United States

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10461, United States

  • NYU Langone Medical Center

    RECRUITING

    New York, New York, 10016, United States

  • National Cancer Center Hospital

    ACTIVE_NOT_RECRUITING

    Chuo-ku, Tokyo, Japan

  • National Cancer Center Hospital East

    ACTIVE_NOT_RECRUITING

    Kashiwa, Chiba, Japan

  • National Hospital Organization Kyushu Cancer Center

    ACTIVE_NOT_RECRUITING

    Fukuoka, Fukuoka, Japan

  • National Hospital Organization Shikoku Cancer Center

    ACTIVE_NOT_RECRUITING

    Matsuyama, Ehime, Japan

  • Northwestern Memorial Hospital

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Oncology Hematology West PC dba Nebraska Cancer Specialists

    RECRUITING

    Omaha, Nebraska, 68130, United States

  • Osaka General Medical Center

    ACTIVE_NOT_RECRUITING

    Osaka, Osaka, Japan

  • Osaka International Cancer Institute

    ACTIVE_NOT_RECRUITING

    Osaka, Osaka, Japan

  • Osaka University Hospital

    ACTIVE_NOT_RECRUITING

    Suita-shi, Osaka, Japan

  • Peking Union Medical College Hospital - Dongdan Campus

    ACTIVE_NOT_RECRUITING

    Beijing, China

  • Piedmont Physician Medical Oncology Atlanta

    RECRUITING

    Atlanta, Georgia, 30318, United States

  • Qinghai University Affiliated Hospital

    ACTIVE_NOT_RECRUITING

    Xining, Qinghai, China

  • Renji Hospital Shanghai Jiaotong Univ School of Medicine

    ACTIVE_NOT_RECRUITING

    Shanghai, Shanghai Municipality, 200127, China

  • Rhode Island Hospital

    RECRUITING

    Providence, Rhode Island, 02903, United States

  • Ruijin Hospital of Shanghai Jiaotong University School of Medicine

    ACTIVE_NOT_RECRUITING

    Shanghai, Shanghai Municipality, China

  • Saint Elizabeth Medical Center Edgewood

    RECRUITING

    Edgewood, Kentucky, 41017, United States

  • Saitama Cancer Center

    ACTIVE_NOT_RECRUITING

    Kitaadachi-gun Ina-machi, Saitama, Japan

  • Saitama Medical University International Medical Center

    ACTIVE_NOT_RECRUITING

    Hidaka-shi, Saitama, Japan

  • Shizuoka Cancer Center

    ACTIVE_NOT_RECRUITING

    Sunto-gun, Shizuoka, Japan

  • Sichuan Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Chengdu, Sichuan, 610200, China

  • Site AU61001

    RECRUITING

    Fitzroy, Australia

  • Site AU61002

    RECRUITING

    Kogarah, New South Wales, Australia

  • Site AU61003

    RECRUITING

    Clayton, Victoria, Australia

  • Site AU61004

    RECRUITING

    Brisbane, Queensland, Australia

  • Site BE32001

    RECRUITING

    Brussels, Belgium

  • Site BE32002

    RECRUITING

    Bonheiden, Belgium

  • Site BE32003

    RECRUITING

    Ghent, Belgium

  • Site BE32004

    RECRUITING

    Liège, Belgium

  • Site BE32005

    RECRUITING

    Leuven, Belgium

  • Site BE32006

    RECRUITING

    Edegem, Belgium

  • Site BR55001

    RECRUITING

    São José do Rio Preto, Brazil

  • Site BR55002

    RECRUITING

    Blumenau, Brazil

  • Site BR55003

    RECRUITING

    Porto Alegre, Brazil

  • Site BR55004

    RECRUITING

    Lages, Brazil

  • Site BR55006

    RECRUITING

    São Caetano do Sul, Brazil

  • Site BR55007

    RECRUITING

    São Paulo, Brazil

  • Site BR55008

    RECRUITING

    Jaú, Brazil

  • Site BR55011

    RECRUITING

    São Paulo, Brazil

  • Site BR55012

    RECRUITING

    Fortaleza, Brazil

  • Site BR55014

    RECRUITING

    Belo Horizonte, Brazil

  • Site CL56001

    RECRUITING

    Santiago, Chile

  • Site CL56004

    RECRUITING

    Las Condes, Chile

  • Site CZ42002

    RECRUITING

    Prague, Czechia

  • Site CZ42003

    RECRUITING

    Prague, Czechia

  • Site CZ42004

    RECRUITING

    Prague, Czechia

  • Site CZ42005

    RECRUITING

    Olomouc, Czechia

  • Site CZ42006

    RECRUITING

    Brno, Czechia

  • Site DE49001

    RECRUITING

    Mainz, Germany

  • Site DE49002

    RECRUITING

    Saarbrücken, Germany

  • Site DE49004

    RECRUITING

    Leipzig, Germany

  • Site DE49006

    RECRUITING

    Nuremberg, Germany

  • Site DE49007

    RECRUITING

    Hanover, Germany

  • Site DE49010

    RECRUITING

    Essen, Germany

  • Site DE49011

    RECRUITING

    Schweinfurt, Germany

  • Site DE49013

    RECRUITING

    Berlin, Germany

  • Site DE49014

    RECRUITING

    Munich, Germany

  • Site DE49016

    RECRUITING

    Wolfsburg, Germany

  • Site DE49017

    RECRUITING

    Frankfurt am Main, Germany

  • Site ES34002

    RECRUITING

    Navarra, Pamplona, Spain

  • Site ES34003

    RECRUITING

    Madrid, Spain

  • Site ES34004

    RECRUITING

    Valencia, Spain

  • Site ES34005

    RECRUITING

    A Coruña, Spain

  • Site ES34006

    RECRUITING

    Barcelona, Spain

  • Site ES34007

    RECRUITING

    Valencia, Spain

  • Site ES34008

    RECRUITING

    Madrid, Spain

  • Site ES34009

    RECRUITING

    Barcelona, Spain

  • Site ES34010

    RECRUITING

    Barcelona, Spain

  • Site ES34011

    RECRUITING

    Barcelona, Spain

  • Site ES34012

    RECRUITING

    Seville, Spain

  • Site ES34013

    RECRUITING

    Pozuelo de Alarcón, Spain

  • Site ES34014

    RECRUITING

    Lleida, Spain

  • Site ES34015

    RECRUITING

    Zaragoza, Spain

  • Site ES34016

    RECRUITING

    Madrid, Spain

  • Site ES34017

    RECRUITING

    Madrid, Spain

  • Site ES34018

    RECRUITING

    Zaragoza, Spain

  • Site ES34019

    RECRUITING

    Madrid, Madrid, Spain

  • Site ES34021

    RECRUITING

    El Palmar, Spain

  • Site ES34022

    RECRUITING

    Elche, Alicante, Spain

  • Site ES34023

    RECRUITING

    San Cugat Del Valles Barcelona, Cataluyna, Spain

  • Site ES34024

    RECRUITING

    Barcelona, Spain

  • Site ES34025

    RECRUITING

    Seville, Spain

  • Site ES34026

    RECRUITING

    Barcelona, Spain

  • Site ES34027

    RECRUITING

    Madrid, Madrid, Spain

  • Site ES34028

    RECRUITING

    Barcelona, Spain

  • Site ES34029

    RECRUITING

    Santiago de Compostela, Spain

  • Site ES34030

    RECRUITING

    Murcia, Spain

  • Site ES34031

    RECRUITING

    Madrid, Spain

  • Site FR33002

    RECRUITING

    Lille, France

  • Site FR33003

    RECRUITING

    Paris, France

  • Site FR33004

    RECRUITING

    Poitiers, France

  • Site FR33005

    RECRUITING

    Dijon, France

  • Site FR33006

    RECRUITING

    Rouen, France

  • Site FR33007

    RECRUITING

    Lille, France

  • Site FR33008

    RECRUITING

    Brest, France

  • Site FR33009

    RECRUITING

    Carassonne, France

  • Site FR33010

    RECRUITING

    Paris, France

  • Site FR33011

    RECRUITING

    Strasbourg, France

  • Site FR33012

    RECRUITING

    Caen, France

  • Site FR33013

    RECRUITING

    Paris, France

  • Site FR33014

    RECRUITING

    Lyon, France

  • Site FR33015

    RECRUITING

    Plérin, France

  • Site FR33016

    RECRUITING

    Bordeaux, France

  • Site FR33017

    RECRUITING

    Lyon, France

  • Site FR33018

    RECRUITING

    Nice, France

  • Site FR33019

    RECRUITING

    Saint Herbian Cedex, France

  • Site FR33020

    RECRUITING

    Montpellier, France

  • Site GB44002

    RECRUITING

    Coventry, United Kingdom

  • Site GB44003

    RECRUITING

    Cardiff, United Kingdom

  • Site GB44004

    RECRUITING

    Glasgow, United Kingdom

  • Site GB44005

    RECRUITING

    London, United Kingdom

  • Site GB44008

    RECRUITING

    Sheffield, United Kingdom

  • Site GB44010

    RECRUITING

    Cottingham, East Riding Of Yorkshire, United Kingdom

  • Site IT39001

    RECRUITING

    Rome, Italy

  • Site IT39002

    RECRUITING

    Verona, Italy

  • Site IT39003

    RECRUITING

    Torrette Di Ancona, Italy

  • Site IT39004

    RECRUITING

    Reggio Emilia, Italy

  • Site IT39006

    RECRUITING

    Cremona, Italy

  • Site IT39007

    RECRUITING

    Meldola, Italy

  • Site IT39009

    RECRUITING

    Brescia, Italy

  • Site IT39011

    RECRUITING

    Florence, Italy

  • Site IT39012

    RECRUITING

    Milan, Italy

  • Site IT39014

    RECRUITING

    Candiolo, Italy

  • Site IT39015

    RECRUITING

    Pisa, Italy

  • Site IT39016

    RECRUITING

    Roma, Italy

  • Site IT39017

    RECRUITING

    Bologna, Italy

  • Site IT39018

    RECRUITING

    Milan, Italy

  • Site IT39019

    RECRUITING

    Bergamo, Italy

  • Site IT39020

    RECRUITING

    Milan, Italy

  • Site IT39021

    RECRUITING

    Naples, Italy

  • Site IT39022

    RECRUITING

    Udine, Italy

  • Site KR82001

    ACTIVE_NOT_RECRUITING

    Seoul, South Korea

  • Site KR82002

    ACTIVE_NOT_RECRUITING

    Seoul, South Korea

  • Site KR82003

    ACTIVE_NOT_RECRUITING

    Seocho-gu, Seoul, South Korea

  • Site KR82004

    ACTIVE_NOT_RECRUITING

    Daegu, South Korea

  • Site KR82005

    ACTIVE_NOT_RECRUITING

    Incheon, South Korea

  • Site KR82006

    ACTIVE_NOT_RECRUITING

    Seoul, South Korea

  • Site KR82007

    ACTIVE_NOT_RECRUITING

    Seongnam-si, Gyeonggi-do, South Korea

  • Site KR82008

    ACTIVE_NOT_RECRUITING

    Seoul, South Korea

  • Site KR82009

    ACTIVE_NOT_RECRUITING

    Cheongju-si, North Chungcheong, South Korea

  • Site KR82010

    ACTIVE_NOT_RECRUITING

    Seoul, South Korea

  • Site KR82011

    ACTIVE_NOT_RECRUITING

    Goyang-si, Gyeonggi-do, South Korea

  • Site KR82012

    ACTIVE_NOT_RECRUITING

    Seoul, South Korea

  • Site KR82013

    ACTIVE_NOT_RECRUITING

    Suwon, Gyeonggi-do, South Korea

  • Site KR82014

    ACTIVE_NOT_RECRUITING

    Hwasungun, Joellanamdo, South Korea

  • Site KR82015

    ACTIVE_NOT_RECRUITING

    Suwon, Gyeonggi-do, South Korea

  • Site LT37001

    RECRUITING

    Kaunas, Lithuania

  • Site LT37002

    RECRUITING

    Vilnius, Lithuania

  • Site MX52001

    RECRUITING

    Oaxaca City, Mexico

  • Site MX52003

    RECRUITING

    Mexico City, Mexico

  • Site NL31001

    RECRUITING

    Nijmegen, Netherlands

  • Site NL31002

    RECRUITING

    Leeuwarden, Netherlands

  • Site PL48001

    RECRUITING

    Brzozów, Woj Podkarpackie, Poland

  • Site PL48002

    RECRUITING

    Przemyśl, Poland

  • Site PL48004

    RECRUITING

    Warsaw, Masovian Voivodeship, Poland

  • Site PL48005

    RECRUITING

    Lubin, Lubusz Voivodeship, Poland

  • Site PL48006

    RECRUITING

    Gliwice, Poland

  • Site PL48007

    RECRUITING

    Warsaw, Poland

  • Site PL48008

    RECRUITING

    Olsztyn, Poland

  • Site PL48009

    RECRUITING

    Swidnica, Poland

  • Site PT35102

    RECRUITING

    Lisbon, Portugal

  • Site PT35103

    RECRUITING

    Braga, Portugal

  • Site PT35104

    RECRUITING

    Guimarães, Portugal

  • Site PT35105

    RECRUITING

    Porto, Portugal

  • Site PT35106

    RECRUITING

    Almada, Portugal

  • Site PT35107

    RECRUITING

    Lisbon, Portugal

  • Site PT35108

    RECRUITING

    Porto, Portugal

  • Site PT35109

    RECRUITING

    Porto, Portugal

  • Site RO40001

    RECRUITING

    Cluj-Napoca, Romania

  • Site RO40002

    RECRUITING

    Floreşti, Romania

  • Site RO40003

    RECRUITING

    Craiova, Romania

  • Site RO40004

    RECRUITING

    Timișoara, Romania

  • Site RO40005

    RECRUITING

    Cluj-Napoca, Romania

  • Site RO40006

    RECRUITING

    Cluj-Napoca, Romania

  • Site RO40007

    RECRUITING

    Iași, Romania

  • Site RO40008

    RECRUITING

    Bucharest, Romania

  • Site TR90001

    RECRUITING

    Ankara, Turkey (Türkiye)

  • Site TR90004

    RECRUITING

    Ankara, Turkey (Türkiye)

  • Site TR90005

    RECRUITING

    Istanbul, Turkey (Türkiye)

  • Site TR90006

    RECRUITING

    Ankara, Turkey (Türkiye)

  • Site TR90009

    RECRUITING

    Samsun, Turkey (Türkiye)

  • Site TR90011

    RECRUITING

    Adana, Turkey (Türkiye)

  • Site TR90013

    RECRUITING

    Konya, Turkey (Türkiye)

  • Site TR90014

    RECRUITING

    Bursa, Turkey (Türkiye)

  • Site TR90015

    RECRUITING

    Van, Turkey (Türkiye)

  • Site TW88601

    ACTIVE_NOT_RECRUITING

    Taichung, Taiwan

  • Site TW88603

    ACTIVE_NOT_RECRUITING

    Dawan, Taiwan, Taiwan

  • Site TW88604

    ACTIVE_NOT_RECRUITING

    Kaohsiung City, Taiwan

  • Site TW88605

    ACTIVE_NOT_RECRUITING

    Taipei, Taiwan

  • Site TW88606

    ACTIVE_NOT_RECRUITING

    Tainan, Taiwan

  • Site UK44001

    RECRUITING

    Bristol, United Kingdom

  • Site UK44006

    RECRUITING

    Dundee, United Kingdom

  • Site UK44009

    RECRUITING

    Manchester, United Kingdom

  • Site UK44011

    RECRUITING

    London, United Kingdom

  • Site UK44014

    RECRUITING

    London, United Kingdom

  • Site UK44015

    RECRUITING

    London, United Kingdom

  • Site UK44016

    RECRUITING

    London, United Kingdom

  • St. Marianna University Hospital

    ACTIVE_NOT_RECRUITING

    Kawasaki-shi, Kanagawa, Japan

  • Sun Yat-sen University - Cancer Center

    ACTIVE_NOT_RECRUITING

    Guangzhou, Guangdong, 510060, China

  • Sun Yat-sen University - Cancer Center

    ACTIVE_NOT_RECRUITING

    Guangzhou, Guangdong, 510555, China

  • TOI Clinical Research

    RECRUITING

    Cerritos, California, 90703, United States

  • Texas Oncology-Baylor Charles A Sammons Cancer Center

    RECRUITING

    Dallas, Texas, 75246, United States

  • The Angeles Clinic and Research Institute, West Los Angeles Office

    RECRUITING

    Los Angeles, California, 90025, United States

  • The Cancer Institute Hospital of JFCR

    ACTIVE_NOT_RECRUITING

    Koto-ku, Tokyo, Japan

  • The Center For Cancer And Blood Disorders (Texas Cancer Care)

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • The First Affiliated Hospital of Zhejiang University

    ACTIVE_NOT_RECRUITING

    Hangzhou, Zhejiang, China

  • The University of Tennessee Medical Center

    RECRUITING

    Knoxville, Tennessee, 37920, United States

  • Tianjin Medical University General Hospital

    ACTIVE_NOT_RECRUITING

    Tianjin, Tianjin Municipality, China

  • Tohoku University Hospital

    ACTIVE_NOT_RECRUITING

    Sendai, Miyagi, Japan

  • UAB Medicine - UAB Hospital

    RECRUITING

    Birmingham, Alabama, 35294, United States

  • University of California, San Diego Moores Cancer Center

    RECRUITING

    La Jolla, California, 92037-0845, United States

  • University of Kansas Cancer Center

    RECRUITING

    Westwood, Kansas, 66205, United States

  • University of Maryland Medical System - University of Maryland Medical Center

    RECRUITING

    Baltimore, Maryland, 21021, United States

  • University of Massachusetts - UMass Chan Medical School

    RECRUITING

    Worcester, Massachusetts, 01655, United States

  • University of Michigan Health System

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 68105, United States

  • University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

  • Utah Cancer Specialists Cancer Center - Medical Oncology

    RECRUITING

    Salt Lake City, Utah, 84106, United States

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

  • Yale University School of Medicine

    RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.